AlphaMark Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

AlphaMark Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,753	Closed	-$13K	–	592
2020 Q2	$13K	Buy	5,753 +600	+12%	+$1.38K	0.01%	332
2020 Q1	$9K	Buy	+5,153	New	+$10.4K	0.01%	320
2019 Q4	–	Sell	-5,000	Closed	-$15K	–	530
2019 Q3	$15K	Hold	5,000	–	–	0.01%	293
2019 Q2	$20K	Sell	5,000 -8	-0.2%	-$42	0.01%	277
2019 Q1	$24K	Hold	5,008	–	–	0.01%	243
2018 Q4	$11K	Hold	5,008	–	–	0.01%	307
2018 Q3	$31K	Buy	5,008 +2,518	+101%	+$13.3K	0.01%	255
2018 Q2	$17K	Hold	2,490	–	–	0.01%	315
2018 Q1	$21K	Sell	2,490 -34,002	-93%	-$282K	0.01%	280
2017 Q4	$339K	Sell	36,492 -1,619	-4%	-$16.3K	0.13%	89
2017 Q3	$445K	Hold	38,111	–	–	0.19%	74
2017 Q2	$1.59M	Hold	38,111	–	–	0.68%	43
2017 Q1	$1.86M	Buy	38,111 +8	+0%	+$313	0.86%	40
2016 Q4	$1.26M	Buy	38,103 +9,750	+34%	+$321K	0.65%	41
2016 Q3	$1.16M	Buy	28,353 +10	+0%	+$392	0.59%	41
2016 Q2	$930K	Hold	28,343	–	–	0.55%	47
2016 Q1	$1.75M	Buy	+28,343	New	+$900K	0.93%	38

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AlphaMark Advisors's GNCA Position: Q3 2020 in Review

AlphaMark Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2020, closing a stake of 5,753 shares — an estimated $13K sold.

AlphaMark Advisors first reported a position in GNCA in Q1 2016 and held it in 17 quarters. The position peaked at $1.86M in Q1 2017. 39 funds tracked by Wall St. Rank hold GNCA as of Q3 2020.

AlphaMark Advisors reported no remaining Genocea Biosciences, Inc. position as of Q3 2020 after selling out during the quarter.
AlphaMark Advisors sold 5,753 Genocea Biosciences, Inc. shares in Q3 2020, an estimated $13K.
AlphaMark Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2016 and held it in 17 quarters.
AlphaMark Advisors's Genocea Biosciences, Inc. position peaked at $1.86M in Q1 2017.
39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2020.

Based on AlphaMark Advisors's 13F filing for Q3 2020, filed 6 Nov 2020.